Article

Patients spectacle-free with trifocal IOL in study

A trifocal diffractive lens (FineVision, PhysIOL) provided spectacle independence for all patients in a short-term study conducted in the United Kingdom, according to Sheraz Daya, FACP, FACS, FRCS(Ed), FRCOphth.

Chicago-A trifocal diffractive lens (FineVision, PhysIOL) provided spectacle independence for all patients in a short-term study conducted in the United Kingdom, according to Sheraz Daya, FACP, FACS, FRCS(Ed), FRCOphth.

Dr. Daya, medical director at the Centre for Sight, West Sussex, England, presented the results of this retrospective trial that included 211 eyes.

The IOL is a hydrophilic acrylate with 25% water content. Using a video to demonstrate implantation, Dr. Daya noted that the haptics are delicate and are best loaded under a microscope. The IOL can be inserted into the eye through a 1.8-mm incision, which is perfect for microincisional cataract surgery, he noted.

One-month follow-up was available for 77% of patients (mean age, 64 years). Of the study eyes, 62 had limbal relaxing incisions for astigmatism that exceeded 0.75 D or more.

The monocular uncorrected distance visual acuity (UDVA) 3 months after surgery was 20/25 in 92% of patients and the binocular UDVA was 20/20 at the same time point in 90% of patients. The intermediate binocular visual acuity at 80 cm was 20/30 at the 3-month time point in about 97% of patients.

Six weeks postoperatively, 8% of patients spontaneously complained of problems with nighttime driving related to glare (grade 2 out of 5). This decreased to 1 out of 5 at the 3-month examination.

“It was very gratifying that every patient was spectacle-free,” Dr. Daya said. “Some glare develops, but it does not substantially affect night-driving. The lens is apodized and patients must be informed that they might struggle with vision, for example, in a restaurant.

“However, this improves over time,” he added. “The purpose of this IOL is to provide good intermediate vision, which it does.”

The IOL is not approved for use in the United States.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.